anti-citrullinated peptide antibody 50 anti-keratin antibody 50

acute myeloid leukaemia 81 aggrecan 139

analysis, discovery driven 121 analysis, hypothesis driven 121 analysis, statistical 121

animal models, for arthritis regulating genes 165

ankylosing spondylitis (AS) 96, 136, 139 anti-CCP antibody 51

anti-citrullinated peptide antibody 50 anti-keratin antibody 50

antiperinuclear factor 50 anti-Sa antibody 50 array hybridisation 120

arthritogenic peptide hypothesis 93 association studies, rheumatoid arthritis 17 autoantibodies 50

autoantigens 93 autoimmune diseases 131 autoimmune arthritis 147

B10.M 133

B27 transgenic rat model 92 bacterial infection 91 BALB/c mouse 135

biobanked patient sample 107 bioinformatics, modelling 125 biomarker 30, 31, 108 biomarker pattern 108 Borrelia burgdorferi 139, 140 C3H mouse 135

cartilage 94 CBF β subunit 80 CD4 132–134

CD4

T-cells 139, 140, 147 CD8

137, 139

CD8

T-cell 93, 94 cellular states 108 Chlamydia 138

Chlamydia trachomatis 91, 92 chondrocyte 134

chondrocyte development 81 chromosomal translocation 81 CIA 134, 135

citrullination 48 citrulline 50 class I 138 class II 135, 138 congenic strain 166 Crohn’s disease 52

cytochrome P450 complex 98 cytokine pattern 96, 134 cytotoxic CD8

T-cell 93

DBA/1 133

diagnostic and prognostic marker 30 disease heterogeneity 30, 33

DNA-ligation-based techniques for molecular analyses 111

DNA microarray technology 33 DNA sequencing 108

DQ8 136

DR1 133, 135

DR4 133, 135, 140

ectopic lymph node 36, 38 enthesitis 136

familial aggregation of RA cases 79 fibroblast-like synoviocyte (FLS) 36 functional polymorphism PD1.3 80

gastric cancer 81

gene expression analysis 163

gene expression profile/profiling 33, 35, 36, 108, 119

gene-based approach, SNPs 45 genetic heterogeneity 167 genetic trait 120 genome scan 13

Genome Screen Meta-Analysis (GSMA) 16 genotyping 108

β-glucan 154

glycosylated forms of CII 134

haplotypes, SNP-based 43 Hapmap project 43 heat shock protein 60 93 hematopoietic development 81 heterogeneity in/of RA 38 high inflammation tissue 36 high-throughput technology 31 HLA 131–133

HLA-B27 91, 95, 136–139

HLA-B27 homodimer (B272) 95, 138 HLA-B27 misfolding hypothesis 95 HLA-B27 subtype 91

HLA-DQ8 135 HLA-DR 135

HLA-DR1 (DRB1*0101) 131, 133 HLA-DR2 140

HLA-DR4 140

HLA-DR4 (DRB1*0401 132–134 HLA-DR4 (DRB1*0402 134, 136 HLA-DR4 (DRB1*0404) 132

HLA-DR4 (DRB1*0405) 132 HLA-DR4 (DRB1*0408) 132 HLA-DR6 (DRB1*1402) 132 HLA-DR10 (DRB1*1001) 132, 133 HLA-DRB1*0401 140

human cartilage glycoprotein 39 (HCgp39) 133, 134

human leukocyte antigens (HLA) Class I 131 human leukocyte antigens (HLA) Class II

131–133

human leukocyte function-associated antigen 1 (LFA-1) 140

humanized mouse 132–134, 140 humanized murine model 139

I-E 133, 135 IFN- γ 134 IL-1 97

IL-10 gene polymorphism 97 immunoreceptor PD-1 79 in situ analyses 111

incomplete penetrance, RA 167 inflammatory bowel disease 91 interleukin-1 gene cluster 97

laser microdissection 121 LD block 45

leukaemia 81 LFA-1 140

linkage analysis 13, 166 linkage association 164 linkage disequilibrium 17

linkage disequilibrium (LD) mapping 43, 45 low inflammation tissue 37

lupus erythematosus, systemic 120 Lyme arthritis 140

Lyme disease 139, 140

major histocompatibility complex (MHC) 131, 137

map-based approach 45 marker gene 125

176

Index

marker, molecular 119 MHC Class I 137

β

-microglobulin (β

m) 137–139 modelling, molecular network 119 molecular mimicry 140

molecular variation among patients 36 monocyte 122

monozygotic twins 90

multifactorial nature of the disease 30 multiparameter screen 120

myeloid leukaemia 81 myofibroblast-like cell 37, 38

NAT9 52 NAT9 83

neutrophilic cytosolic factor 1 (Ncf1) 167 NOD 2 (CARD15) genotype 97

organic cation transporter gene SLC22A4 52, 83 outer surface protein A (OspA) 140

parallel genotyping 108, 111 PDCD1 52

peptidylarginine deiminase type 4 (PADI4) 45, 48

peripheral arthritis 136

personalised medicine/therapy 29, 39 pharmacogenetics 168

polygenic inheritance 167 population stratification 20 positional cloning 164, 166 positive and negative selection 151 prevalence of RA 11

protein array 31

protein expression profiling 38 protein measurement 110 protein modification 122 proteoglycan 133, 135

proteoglycan induced arthritis (PGIA) 135 proteomics 38

psoriasis 52, 83 PTPN22 156

reactive arthritis (ReA) 89, 96, 137 regulatory T (T

) cell 151 reverse genetics 166

runt-domain-encoding genes 80 RUNX1 52, 80

RUNX2 80 RUNX3 80

RUNX3 in inflammation 82

sacroiliitis 136

Salmonella enteritides 95 self-reactive CD4

T-cell 147 shared epitope 136

sibling risk ratio 12

signal transduction in T-cell 151 signalling, extracellular 123 signalling, intracellular 123 SLC22A4 52, 83

SLC22A5 52 SLC9A3R1 52 SLC9A3R1 83 SNPs 43

spondyloarthritides (Spa) 89 spondyloarthropathy 136, 138

stratification, diagnostic, therapeutic 120 synoviocyte 36

synovitis 147

systemic lupus erythematosus 120

TGF- β 82, 97 Th1 139

Th2 cytokines 139 TNF- α 96, 134 TNF- α gene 96 TNF-α microsatellite 96 total genetic risk in AS 96 transcriptome, analysis 119

transcriptome, biological importance 122

transcriptome, biological system 121

transcriptome, cell infiltration 122

transcriptome, cellular composition 122

transcriptome, functional signature 120

transcriptome, mRNA abundance 122 transforming growth factor (TGF) beta 82, 97 type II collagen (CII) 133–136

tyrosine phosphatase 61, 65

whole genome scan 13

Yersinia enterocolitica 92 Yersinnia pestis 71

ZAP-70 147 zymosan 154

178

Index

Homepage: http://www.birkhauser.ch

Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered inclu- de vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signalling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates.

Available volumes:

T Cells in Arthritis, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998 Chemokines and Skin, E. Kownatzki, J. Norgauer (Editors), 1998

Medicinal Fatty Acids, J. Kremer (Editor), 1998 Inducible Enzymes in the Inflammatory Response,

D.A. Willoughby, A. Tomlinson (Editors), 1999

Cytokines in Severe Sepsis and Septic Shock, H. Redl, G. Schlag (Editors), 1999 Fatty Acids and Inflammatory Skin Diseases, J.-M. Schröder (Editor), 1999 Immunomodulatory Agents from Plants, H. Wagner (Editor), 1999 Cytokines and Pain, L. Watkins, S. Maier (Editors), 1999

In Vivo Models of Inflammation, D. Morgan, L. Marshall (Editors), 1999 Pain and Neurogenic Inflammation, S.D. Brain, P. Moore (Editors), 1999 Anti-Inflammatory Drugs in Asthma, A.P. Sampson, M.K. Church (Editors), 1999 Novel Inhibitors of Leukotrienes, G. Folco, B. Samuelsson, R.C. Murphy (Editors), 1999 Vascular Adhesion Molecules and Inflammation, J.D. Pearson (Editor), 1999

Metalloproteinases as Targets for Anti-Inflammatory Drugs, K.M.K. Bottomley, D. Bradshaw, J.S. Nixon (Editors), 1999

Free Radicals and Inflammation, P.G. Winyard, D.R. Blake, C.H. Evans (Editors), 1999 Gene Therapy in Inflammatory Diseases, C.H. Evans, P. Robbins (Editors), 2000 New Cytokines as Potential Drugs, S. K. Narula, R. Coffmann (Editors), 2000 High Throughput Screening for Novel Anti-inflammatories, M. Kahn (Editor), 2000 Immunology and Drug Therapy of Atopic Skin Diseases,

C.A.F. Bruijnzeel-Komen, E.F. Knol (Editors), 2000

Novel Cytokine Inhibitors, G.A. Higgs, B. Henderson (Editors), 2000

Inflammatory Processes. Molecular Mechanisms and Therapeutic Opportunities,

L.G. Letts, D.W. Morgan (Editors), 2000

Backlist

Cellular Mechanisms in Airways Inflammation, C. Page, K. Banner, D. Spina (Editors), 2000 Inflammatory and Infectious Basis of Atherosclerosis, J.L. Mehta (Editor), 2001

Muscarinic Receptors in Airways Diseases, J. Zaagsma, H. Meurs, A.F. Roffel (Editors), 2001 TGF- β and Related Cytokines in Inflammation, S.N. Breit, S. Wahl (Editors), 2001

Nitric Oxide and Inflammation, D. Salvemini, T.R. Billiar, Y. Vodovotz (Editors), 2001 Neuroinflammatory Mechanisms in Alzheimer’s Disease. Basic and Clinical Research,

J. Rogers (Editor), 2001

Disease-modifying Therapy in Vasculitides,

C.G.M. Kallenberg, J.W. Cohen Tervaert (Editors), 2001 Inflammation and Stroke, G.Z. Feuerstein (Editor), 2001 NMDA Antagonists as Potential Analgesic Drugs,

D.J.S. Sirinathsinghji, R.G. Hill (Editors), 2002

Migraine: A Neuroinflammatory Disease? E.L.H. Spierings, M. Sanchez del Rio (Editors), 2002 Mechanisms and Mediators of Neuropathic pain, A.B. Malmberg, S.R. Chaplan (Editors),

2002

Bone Morphogenetic Proteins. From Laboratory to Clinical Practice, S. Vukicevic, K.T. Sampath (Editors), 2002

The Hereditary Basis of Allergic Diseases, J. Holloway, S. Holgate (Editors), 2002 Inflammation and Cardiac Diseases, G.Z. Feuerstein, P. Libby, D.L. Mann (Editors), 2003 Mind over Matter – Regulation of Peripheral Inflammation by the CNS,

M. Schäfer, C. Stein (Editors), 2003

Heat Shock Proteins and Inflammation, W. van Eden (Editor), 2003

Pharmacotherapy of Gastrointestinal Inflammation, A. Guglietta (Editor), 2004 Arachidonate Remodeling and Inflammation, A.N. Fonteh, R.L. Wykle (Editors), 2004 Recent Advances in Pathophysiology of COPD, P.J. Barnes, T.T. Hansel (Editors), 2004 Cytokines and Joint Injury, W.B. van den Berg, P. Miossec (Editors), 2004

Cancer and Inflammation, D.W. Morgan, U. Forssmann, M.T. Nakada (Editors), 2004 Bone Morphogenetic Proteins: Bone Regeneration and Beyond, S. Vukicevic, K.T. Sampath

(Editors), 2004

Antibiotics as Anti-Inflammatory and Immunomodulatory Agents, B.K. Rubin, J. Tamaoki (Editors), 2005

Antirheumatic Therapy: Actions and Outcomes, R.O. Day, D.E. Furst, P.L.C.M. van Riel, B. Bresnihan (Editors), 2005

Regulatory T-Cells in Inflammation, L. Taams, A.N. Akbar, M.H.M Wauben (Editors), 2005 Sodium Channels, Pain, and Analgesia, K. Coward, M. Baker (Editors), 2005

Turning up the Heat on Pain: TRPV1 Receptors in Pain and Inflammation, A.B Malmberg, K.R. Bley (Editors), 2005

The NPY Family of Peptides in Immune Disorders, Inflammation, Angiogenesis and Cancer, Z. Zukowska, G. Z. Feuerstein (Editors), 2005

Complement and Kidney Disease, P. F. Zipfel (Editor), 2005

Chemokine Biology – Basic Research and Clinical Application, Volume 1: Immunobiology of Chemokines, B. Moser, G. L. Letts, K. Neote (Editors), 2006

Toll-like Receptors in Inflammation, L.A.J. O’Neill, E. Brint (Editors), 2006